Ge Rongbin, Wang Zongwei, Cheng Liang
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Department of Surgery, Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
NPJ Precis Oncol. 2022 May 4;6(1):31. doi: 10.1038/s41698-022-00272-w.
Prostate cancer is characterized by a high degree of heterogeneity, which poses a major challenge to precision therapy and drug development. In this review, we discuss how nongenetic factors contribute to heterogeneity of prostate cancer. We also discuss tumor heterogeneity and phenotypic switching related to anticancer therapies. Lastly, we summarize the challenges targeting the tumor environments, and emphasize that continued exploration of tumor heterogeneity is needed in order to offer a personalized therapy for advanced prostate cancer patients.
前列腺癌具有高度异质性，这给精准治疗和药物开发带来了重大挑战。在这篇综述中，我们讨论了非遗传因素如何导致前列腺癌的异质性。我们还讨论了与抗癌治疗相关的肿瘤异质性和表型转换。最后，我们总结了针对肿瘤微环境的挑战，并强调需要持续探索肿瘤异质性，以便为晚期前列腺癌患者提供个性化治疗。
